Skip to main content

J&J Opposes Spoliation Of Evidence Claim In Talcum MDL

J&J Opposes Spoliation Of Evidence Claim In Talcum MDL

J&J Opposes Spoliation Of Evidence Claim In Talcum MDL

Introduction

Talcum powder giant Johnson & Johnson (J&J) and its subsidiary Johnson & Johnson Consumer Inc. filed a response over the Plaintiffs’ Steering Committee's (PSC) motion to add a spoliation of evidence claim to the First Amended Master Long Form Complaint.

According to the January 12 opposition brief, the defendants argued that it's untimely for the plaintiffs to add the claim four years after the first Amended Master Long Form Complaint was filed. The defendants further added that the court had issued rulings on the admissibility of expert witness testimony eight months back, clearing the way for individual bellwether cases to proceed for the trial.

The motion to amend the Master Complaint was filed in December by the PSC. The motion noted that J&J failed to preserve samples of talc tested for asbestos and documents linked to industrial talc products and other illnesses. J&J was also alleged of destroying documents linked to a talc mine and its baby powder.

The lawsuits over talc-based products are growing in numbers, each alleging that the users were exposed to talc and asbestos particles present in the products, which resulted in ovarian cancer and other injuries.

The result of the bellwether trials will not hold an obligation on other cases, and the company is facing immense pressure to negotiate a settlement as the company has not established that it can strongly defend its conduct at trial.

J&J is currently facing more than 20,000 Baby Powder and Shower-to-Shower lawsuits and has been paying in millions to resolve them. Last year the company stopped selling its talcum-based products in the U.S. and Canada, claiming declined consumer demand and misinformation about the safety of the products.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

Purdue, Sacklers Agree to New $7.4B Opioid Settlement

Categories: Opioids

All 50 U.S. states, along with the District of Columbia and U.S. territories, have agreed to a $7.4 billion settlement with Purdue Pharma, the manufacturer of OxyContin.

This deal addresses allegations that the company’s aggressive and…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!